SCHEDULE 13D/A: EcoR1 Capital Maintains Significant Prothena Stake Amidst Director Resignation

EcoR1 Capital, LLC and its affiliates report a continued 21.5% beneficial ownership in Prothena Corporation plc, while Oleg Nodelman, a key figure, has resigned from Prothena's board of directors.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. collectively beneficially own 11,584,280 Ordinary Shares of Prothena Corporation plc.
• This aggregate ownership represents 21.5% of Prothena's outstanding Ordinary Shares, based on 53,808,732 shares outstanding as of November 6, 2024.
• EcoR1 Capital Fund Qualified, L.P. specifically holds 10,847,852 shares, accounting for 20.2% of the class.
• The reporting persons acquired these shares for investment purposes, believing Prothena's Ordinary Shares were undervalued and represented an attractive investment opportunity at the time of purchase.
• A total of $125,156,531 in working capital was used by the Funds to purchase the Issuer's Ordinary Shares.
• Oleg Nodelman, who was previously appointed to Prothena's board of directors, resigned from his position on December 31, 2024.

Sentiment

Score: 5

Explanation: The document is primarily factual, reporting on beneficial ownership and a board resignation. The investor's stated belief in undervaluation is positive, but the director's resignation could be interpreted neutrally or with slight concern regarding direct investor representation, balancing the overall sentiment to neutral.

Positives

• The reporting persons acquired shares based on their belief that Prothena's Ordinary Shares were undervalued and represented an attractive investment opportunity.
• The significant beneficial ownership stake (21.5%) by EcoR1 Capital and its affiliates indicates a strong conviction in the Issuer's long-term potential.

Negatives

• Oleg Nodelman, a representative of a major shareholder (EcoR1 Capital), resigned from Prothena's board of directors, removing direct investor representation from the board.

Future Outlook

The reporting persons intend to routinely monitor Prothena Corporation plc, considering factors such as trading prices, operations, assets, prospects, financial position, business development, management, competitive and strategic matters, and general economic conditions. They may take various actions regarding their holdings, including purchasing additional shares, selling existing shares, entering into or unwinding hedging transactions, or pledging shares for liquidity. While they have no present plans for specific corporate actions, they may recommend actions to Prothena's management, board, and stockholders, potentially involving mergers, consolidations, asset sales or acquisitions, changes in control, or other changes in capitalization.

Management Comments

• "The reporting persons acquired Ordinary Shares for investment purposes based on their belief that the Issuer's Ordinary Shares, when purchased, was undervalued and represented an attractive investment opportunity."
• "The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Ordinary Shares and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations."
• "The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the reporting persons may recommend action to the Issuer's management, board of directors and stockholders."

Industry Context

This filing highlights the continued significant investment and active engagement of a specialized healthcare investment firm, EcoR1 Capital, in Prothena Corporation plc, a biopharmaceutical company. Such substantial beneficial ownership and the associated board representation (or its cessation) are common in the biotech sector, where strategic investor influence can be crucial for companies navigating drug development, clinical trials, and commercialization pathways.

Management Changes

Corporate Governance

Legal Proceedings

• None of the reporting persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• None of the reporting persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

• EcoR1 Capital, LLC serves as an investment adviser to investment funds, including EcoR1 Capital Fund Qualified, L.P., and is the general partner of these funds.
• Pursuant to investment management agreements and limited partnership agreements, EcoR1 Capital, LLC is entitled to allocations and fees based on assets under management and realized/unrealized gains from its advisory and general partner roles.

Stakeholder Impact

• **Shareholders**: Provides transparency regarding a significant shareholder's continued large stake and future intentions, which could influence investor sentiment and trading decisions. The resignation of a director representing a major shareholder may also be a point of interest.
• **Management/Board**: The change in board composition due to Oleg Nodelman's resignation impacts the board's dynamics. The stated intent of the reporting persons to potentially recommend actions to management and the board indicates ongoing shareholder engagement and potential for strategic influence.
• **Employees, Customers, Suppliers, Creditors**: Direct impact is minimal, as the filing primarily concerns ownership and governance, not operational changes or financial performance directly affecting these groups.

Next Steps

• Reporting persons will routinely monitor Prothena Corporation plc's performance and market conditions.
• Reporting persons may purchase additional Ordinary Shares or sell existing holdings in the open market or through private transactions.
• Reporting persons may enter into or unwind hedging or other derivative transactions related to Ordinary Shares.
• Reporting persons may pledge their interests in Ordinary Shares to obtain liquidity.
• Reporting persons may communicate with other stockholders, industry participants, and interested parties about Prothena.
• Reporting persons may recommend actions to Prothena's management, board of directors, and stockholders, potentially involving significant corporate events.

Key Dates

Keywords

Prothena Corporation plc, EcoR1 Capital, Oleg Nodelman, Schedule 13D/A, Beneficial Ownership, Investment, Ordinary Shares, Corporate Governance, Biotechnology, Pharmaceutical, Shareholder Activism